TriangleHEALTH PROFESSIONAL · SOURCE READING
Intermediate Prognosis
Source: Testicular Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for Testicular Cancer
Nonseminoma:
Testis/retroperitoneal primary, and
No nonpulmonary visceral metastases, and
Intermediate markers–any of: *[Note: N indicates the upper limit of normal for the LDH assay.]
Intermediate markers–any of: *[Note: N indicates the upper limit of normal for the LDH assay.]
AFP 1,000 ng/mL or more and 10,000 ng/mL or less, or
Intermediate markers–any of: *[Note: N indicates the upper limit of normal for the LDH assay.]
Beta-hCG 5,000 IU/L or more and 50,000 IU/L or less, or
Intermediate markers–any of: *[Note: N indicates the upper limit of normal for the LDH assay.]
LDH 1.5 or more × N* and less than 10 × N*
A total of 13% to 28% of nonseminomas are intermediate prognosis. The 5-year PFS rate is 75%; the 5-year survival rate is 80%–83%.
Seminoma:
Any primary site, and
Nonpulmonary visceral metastases, and
Normal AFP, any beta-hCG, any LDH
A total of 10% of seminomas are intermediate prognosis. The 5-year PFS rate is 67%; the 5-year survival rate is 72%.
Preserved source evidence · Not medical advice